Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population

Roche provides update on astegolimab in chronic obstructive pulmonary disease

The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks

Lupin achieves GMP certification from TGA Australia for Dabhasa API facility

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva

PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization

The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development

Cupid invests in GII Healthcare Investment

GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India

GlaxoSmithKline Pharmaceuticals appoints Vishwanath Swarup as Commercial Head - General Medicines

Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines

82% of people prefer diagnostic centers over hospitals for preventive checkups in India

Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities

Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab

Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab